Gender differences in risk factor management and pharmacological treatment among CHD patients: Belgian results of the EUROASPIRE IV and EUROASPIRE V surveys-Reference-Cited by-同舟云学术

Gender differences in risk factor management and pharmacological treatment among CHD patients: Belgian results of the EUROASPIRE IV and EUROASPIRE V surveys

Published:2023-02-13 Issue:5 Volume:78 Page:607-613
ISSN:0001-5385
Container-title:Acta Cardiologica
language:en
Short-container-title:Acta Cardiologica

Author:

Vynckier Pieter¹,De Sutter Johan²³,De Pauw Michel³⁴,Vandekerckhove Hans⁵,De Backer Guy¹,Vervaet Pieter⁴,Deweerdt Nancy⁵,Dendale Paul⁶,Persu Alexandre⁷,Janssen Arne⁶,Chenu Patrick⁷,Kotseva Kornelia⁸⁹,Gevaert Sofie¹⁰,De Bacquer Dirk¹,De Smedt Delphine¹,

Affiliation:

1. Department of Public Health and Primary Care, Ghent University, Ghent, Belgium

2. Department of Cardiology, AZ Maria Middelares, Gent, Belgium

3. Department of Internal Medicine, Ghent University, Ghent, Belgium

4. Department of Cardiology, Ghent University Hospital, Ghent, Belgium

5. Department of Cardiology, AZ Sint Lucas, Ghent, Belgium

6. Heart Centre Hasselt, Jessa Hospital and University of Hasselt, Hasselt, Belgium

7. Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires Saint-Luc and Pole of Cardiovascular Research, Institute de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium

8. National Institute for Prevention and Cardiovascular Health, National University of Ireland, Galway, Ireland

9. Imperial College Healthcare NHS Trust, London, UK

10. Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium

Funder

European Society of Cardiology

EURObservational Research Programme

Amarin

Amgen

Daiichi Sankyo

Eli Lilly

Ferrer

Novo Nordisk